Search Results - "Junker, Anders"

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials by Vilsbøll, Tina, Christensen, Mikkel, Junker, Anders E, Knop, Filip K, Gluud, Lise Lotte

“…Objective To determine whether treatment with agonists of glucagon-like peptide-1 receptor (GLP-1R) result in weight loss in overweight or obese patients with…”
Get full text

Rationale and design of DanGer shock: Danish-German cardiogenic shock trial by Udesen, Nanna Junker, Møller, Jacob Eifer, Lindholm, Matias Greve, Eiskjær, Hans, Schäfer, Andreas, Werner, Nikos, Holmvang, Lene, Terkelsen, Christian Juhl, Jensen, Lisette Okkels, Junker, Anders, Schmidt, Henrik, Wachtell, Kristian, Thiele, Holger, Engstrøm, Thomas, Hassager, Christian

“…The DanGer Shock trial test the hypothesis that left ventricular (LV) mechanical circulatory support with Impella CP transvalvular microaxial flow pump…”
Get full text

Fractional Flow Reserve Versus Angiographically-Guided Coronary Artery Bypass Grafting by Thuesen, Anne Langhoff, Riber, Lars Peter, Veien, Karsten Tange, Christiansen, Evald Høj, Jensen, Svend Eggert, Modrau, Ivy, Andreasen, Jan Jesper, Junker, Anders, Mortensen, Poul Erik, Jensen, Lisette Okkels

“…The value of fractional flow reserve (FFR) evaluation of coronary artery stenosis in coronary artery bypass grafting (CABG) is uncertain, and stenosis…”
Get full text

Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease by Niu, Lili, Geyer, Philipp E, Wewer Albrechtsen, Nicolai J, Gluud, Lise L, Santos, Alberto, Doll, Sophia, Treit, Peter V, Holst, Jens J, Knop, Filip K, Vilsbøll, Tina, Junker, Anders, Sachs, Stephan, Stemmer, Kerstin, Müller, Timo D, Tschöp, Matthias H, Hofmann, Susanna M, Mann, Matthias

“…Non‐alcoholic fatty liver disease (NAFLD) affects 25% of the population and can progress to cirrhosis with limited treatment options. As the liver secretes…”
Get full text

The role of incretin hormones and glucagon in patients with liver disease by Junker, Anders Ellekær

“…Non-alcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis exceeding 5% of hepatocytes with no other reason for hepatic fat accumulation. The…”
Get full text

Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes by Wewer Albrechtsen, Nicolai J, Junker, Anders E, Christensen, Mette, Hædersdal, Sofie, Wibrand, Flemming, Lund, Allan M, Galsgaard, Katrine D, Holst, Jens J, Knop, Filip K, Vilsbøll, Tina

“…Patients with type 2 diabetes (T2D) and patients with nonalcoholic fatty liver disease (NAFLD) frequently exhibit elevated plasma concentrations of glucagon…”
Get more information

Oral glucose has little or no effect on appetite and satiety sensations despite a significant gastrointestinal response by Lauritsen, Julius V, Bergmann, Natasha, Junker, Anders E, Gyldenløve, Mette, Skov, Lone, Gluud, Lise L, Hartmann, Bolette, Holst, Jens J, Vilsbøll, Tina, Knop, Filip K

“…The effect of oral glucose-induced release of gastrointestinal hormones on satiety and appetite independently of prevailing plasma glucose excursions is…”
Get full text

Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose by Maagensen, Henrik, Junker, Anders E, Jørgensen, Niklas R, Gluud, Lise L, Knop, Filip K, Vilsbøll, Tina

“…Nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes (T2D) and vice versa, and both conditions are associated with an increased risk of…”
Get full text

Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial by Raungaard, Bent, Dr, Jensen, Lisette Okkels, DMSci, Tilsted, Hans-Henrik, MD, Christiansen, Evald Høj, PhD, Maeng, Michael, PhD, Terkelsen, Christian Juhl, DMSci, Krusell, Lars Romer, MD, Kaltoft, Anne, PhD, Kristensen, Steen Dalby, Prof, Bøtker, Hans Erik, Prof, Thuesen, Leif, DMSci, Aarøe, Jens, MD, Jensen, Svend Eggert, PhD, Villadsen, Anton Boel, MD, Thayssen, Per, DMSci, Veien, Karsten Tange, MD, Hansen, Knud Nørregaard, MD, Junker, Anders, MD, Madsen, Morten, MSc, Ravkilde, Jan, DMSci, Lassen, Jens Flensted, PhD

“…Summary Background New-generation drug-eluting coronary stents have reduced the risk of coronary events, especially in patients with complex disease or…”
Get full text

Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease by Jensen, Anne-Sofie H, Ytting, Henriette, Werge, Mikkel P, Rashu, Elias B, Hetland, Liv E, Thing, Mira, Nabilou, Puria, Burisch, Johan, Bojsen-Møller, Kirstine N, Junker, Anders E, Hobolth, Lise, Mortensen, Christian, Tofteng, Flemming, Bendtsen, Flemming, Møller, Søren, Vyberg, Mogens, Serizawa, Reza R, Gluud, Lise L, Wewer Albrechtsen, Nicolai J

“…Autoimmune liver diseases are associated with an increased risk of diabetes, yet the underlying mechanisms remain unknown. In this cross-sectional study, we…”
Get more information

Experience from a COVID-19 first-line referral clinic in Greater Copenhagen by Kronborg, Thit Mynster, Kimer, Nina, Junker, Anders Ellekær, Werge, Mikkel Parsberg, Gluud, Lise Lotte, Ytting, Henriette

“…Due to the coronavirus disease 2019 (COVID-19) exposure in Denmark, first-line referral centres were established to handle all patients suspected of COVID-19…”
Get full text

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease by Junker, Anders E, Gluud, Lise L, van Hall, Gerrit, Holst, Jens J, Knop, Filip K, Vilsbøll, Tina

“…Background & Aims We evaluated the glucagon-suppressive effect of glucagon-like peptide-1 (GLP-1) and its potential effects on endogenous glucose production…”
Get full text

Dopamine agents for hepatic encephalopathy by Junker, Anders Ellekær, Als-Nielsen, Bodil, Gluud, Christian, Gluud, Lise Lotte

“…Patients with hepatic encephalopathy may present with extrapyramidal symptoms and changes in basal ganglia. These changes are similar to those seen in patients…”
Get more information

Postprandial dysfunction in fatty liver disease by Grandt, Josephine, Jensen, Anne‐Sofie H., Werge, Mikkel P., Rashu, Elias B., Møller, Andreas, Junker, Anders E., Hobolth, Lise, Mortensen, Christian, Johansen, Christian D., Vyberg, Mogens, Serizawa, Reza Rafiolsadat, Møller, Søren, Gluud, Lise Lotte, Wewer Albrechtsen, Nicolai J.

“…Fatty liver disease has mainly been characterized under fasting conditions. However, as the liver is essential for postprandial homeostasis, identifying…”
Get full text

Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy by Jensen, Berit E S, Hansen, Jane M, Larsen, Kasper S, Junker, Anders B, Lassen, Jens F, Jensen, Svend E, Schaffalitzky de Muckadell, Ove B

“…Dual antiplatelet therapy reduces the risk of ischemic complications after acute coronary syndrome, but increases the risk of bleeding including upper…”
Get full text

Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis by Junker, Anders E, Gluud, Lise L, Holst, Jens J, Knop, Filip K, Vilsbøll, Tina

“…Background and Aim The impaired glucose tolerance in cirrhosis is poorly understood. We evaluated the influence of gastrointestinal‐mediated glucose disposal…”
Get full text

15O-Water Positron Emission Tomography of Myocardial Ischemia in Patients Referred for Percutaneous Coronary Intervention by Bendix, Kristoffer, Thomassen, Anders, Junker, Anders, Veien, Karsten Tange, Jensen, Lisette Okkels

“…The diagnostic accuracy of non-invasive diagnostic methods for detecting coronary artery disease has increased in recent years. This study aimed to assess the…”
Get full text

Optimal lesion preparation before implantation of a Magmaris bioresorbable scaffold in patients with coronary artery stenosis: Rationale, design and methodology of the OPTIMIS study by Hansen, Kirstine Nørregaard, Maehara, Akiko, Noori, Manijeh, Trøan, Jens, Fallesen, Christian Oliver, Hougaard, Mikkel, Ellert-Gregersen, Julia, Veien, Karsten Tange, Junker, Anders, Hansen, Henrik Steen, Lassen, Jens Flensted, Jensen, Lisette Okkels

“…Percutaneous coronary intervention with implantation of a bioresorbable scaffold (BRS) provide the vessel support for a limited period allowing the vessel to…”
Get full text

Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction by Jensen, Lisette Okkels, MD, DMSci, PhD, Terkelsen, Christian Juhl, MD, PhD, Horváth-Puhó, Erzsébet, MSc, PhD, Tilsted, Hans-Henrik, MD, Maeng, Michael, MD, PhD, Junker, Anders, MD, PhD, Lassen, Jens Flensted, MD, PhD, Thuesen, Leif, MD, DMSci, Sørensen, Henrik Toft, MD, DMSci, PhD, Thayssen, Per, MD, DMSci

“…Background In patients with ST-segment elevation myocardial infarction (STEMI), timely reperfusion with primary percutaneous coronary intervention (PCI) is the…”
Get full text

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus - and Sirolimus -Eluting Stents (from the SORT OUT IV Trial) by Jensen, Lisette Okkels, MD, DMSci, PhD, Thayssen, Per, MD, DMSci, Junker, Anders, MD, PhD, Maeng, Michael, MD, PhD, Tilsted, Hans-Henrik, MD, Kaltoft, Anne, MD, PhD, Hansen, Knud Nørregaard, MD, Christiansen, Evald Høj, MD, PhD, Kristensen, Steen Dalby, MD, DMSci, Ravkilde, Jan, MD, DMSci, Madsen, Morten, MSc, Sørensen, Henrik Toft, MD, DMSci, PhD, Thuesen, Leif, MD, DMSci, Lassen, Jens Flensted, MD, PhD

“…Diabetes is associated with increased risk of major adverse cardiac events (MACEs) after percutaneous coronary intervention. The purpose of this substudy of…”
Get full text